Menu Search
Equities

Aurora Cannabis Inc

21P:FRA

Aurora Cannabis Inc

Actions
  • Price (EUR)6.76
  • Today's Change-0.245 / -3.50%
  • Shares traded17.81k
  • 1 Year change+21.85%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 20:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Bradford Ontario, Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.

  • Revenue in CAD (TTM)266.97m
  • Net income in CAD-125.07m
  • Incorporated2006
  • Employees1.13k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ACB:TOR since
announced		Transaction
value
Indica Industries Pty LtdDeal completed08 Feb 202408 Feb 2024Deal completed93.27%33.02m
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.